Palatin Technologies Inc. (PTN)
| Bid | 0.19 |
| Market Cap | 5.6M |
| Revenue (ttm) | 350K |
| Net Income (ttm) | -26.95M |
| EPS (ttm) | -1.54 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | 0.48 |
| Analyst | Buy |
| Ask | 0.2 |
| Volume | 45,047,838 |
| Avg. Volume (20D) | 1,124,280 |
| Open | 0.21 |
| Previous Close | 0.17 |
| Day's Range | 0.17 - 0.21 |
| 52-Week Range | 0.16 - 2.48 |
| Beta | 0.90 |
About PTN
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatmen...
Analyst Forecast
According to 1 analyst ratings, the average rating for PTN stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 3417.59% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call TranscriptPalatin Technologies, Inc. (NYSE:PTN ) Q2 2025 Earnings Conference Call February 13, 2024 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secret...